Product name
Method of Producing Homologous Cellular Blood Components from Hematopoietic Progenitor CellsSummary
Alternative sources for cellular blood components are of great interest. An autologous cell culture system for the production of high yields of blood cell components, which is easy to establish without the need for severe invasive procedures is needed.Organization name
ipal GmbHProfile
Technology
Vein endothelial cells from an umbilical cord and HPC from the umiblical cord blood of the same donor are isolated. After culturing the endothelian cells in the presence of a single stimulant, culture supernatant comprising cell-released endothelian factors is collected. Now the isolated undifferentiated HPC are cultivated with the collected supernatant together with fresh HPC medium and differentiate to mature granulocytes, thrombocytes or erythrocytes. Cell type differentation depends on the single immun stimulant with which the endothelian cells get stimulated before.
Commercial Opportunity
- 4,45 million transfusion units (tu) of erythrocyte concentrates, 381000 tu thrombocyte concentrates and 500-1000 tu granulocyte concentrates are transfused each year in Germany
- Willingness to donate blood decreases
- Erythrocyte concentrates of blood type 0 (Rh-) which can be transfused without cross-matching is of rare supply
- Costs per transfusion unit increases due to increasing number of predescribed screening tests for infectious diseases (HIV, hepatitits A, B, C virus, siphilis) as well as procedures for inactivation of pathogens
- Remaining risk for transferring rare diseases or for which no inexpensive test is available (SARS, West Nile Virus, ...) still exists
- Thrombocyte and granulocyte concentrates require expensive apheresis systems
- Production of granulocyte concentrates is accompanied by the interventional sedimentation of erythrocytes using hydroxyethyl starch (HES) which can cause side effects such as allergic reactions or liquid retention
Developmental Status
Lab Level: In one embodiment the yields of said cellular blood component in relation to the initial number of hematopoietic progenitor cells, is:
- in case of granulocytes more than 1000-fold
- in case of thrombocytes more than 10.000-fold
- in case of erythrocytes more than 100.000-fold
Patent Situation
European application has been filed.
The technology was developed at the Charité Universitätsmedizin (Berlin/Germany) and is offered by Ipal.
Contact:
ipal GmbH
Marcel Tilmann
Project Leader
marcel.tilmann(at)ipal.de
About IPAL
The ipal GmbH patent agency assesses and markets the inventions of scientists in the area of Life Sciences and Physics & Engineering from Charité-Universitätsmedizin (University Medicine), Robert Koch Institute, Deutsches Herzzentrum (German Heart Institute), Bundesanstalt für Materialprüfung (BAM - Federal Institute for Materials Research and Testing), the Zuse Institute as well as the Paul Ehrlich Institute, Langen and the Jacobs University Bremen. IPAL provides all of the services necessary - from the assessment of patentable technologies to a comprehensive patent protection all the way to the evaluation of sales returns potentials on the market and successful commercialisation through the use of licensing agreements.
Description File
Method_of_Producing_Homologous_Cellular_Blood_Components_from_Hemato...
print this page
